Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA4 | P22748 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21078389 | 0.82 | POLB (0.68) | POLBCA12CA1CA2CA4 | |
| SCHEMBL29888792 | 0.81 | POLB (0.74) | POLBCA12CA1CA2CA4 | |
| SCHEMBL29380162 | 0.81 | POLB (1.00) | POLBCA12CA1CA2CA4 | |
| SCHEMBL1482567 | 0.81 | POLB (0.74) | POLBCA12CA1CA2CA4 | |
| SCHEMBL144989 | 0.81 | POLB (1.00) | POLBCA12CA1CA2CA4 | |
| SCHEMBL4041618 | 0.80 | POLB (0.65) | POLBCA12CA1CA2CA4 | |
| SCHEMBL2146864 | 0.79 | POLB (0.71) | POLBCA12CA1CA2CA4 | |
| SCHEMBL9460748 | 0.79 | POLB (0.71) | POLBCA12CA1CA2CA4 | |
| SCHEMBL9136394 | 0.79 | POLB (0.95) | POLBCA12CA1CA2CA4 | |
| SCHEMBL9134919 | 0.79 | POLB (0.95) | POLBCA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0238657-B1 | ANTIVIRAL IMMUNOTHERAPEUTIC AGENT AND PREPARATION THEREOF | VETREPHARM RESEARCH, INC. (US) | 1992-03-11 | — | — | EP | claimed |
| US-4946853-A | Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method | ELAN TRANSDERMAL LIMITED (IE) | 1990-08-07 | — | — | US | claimed |
| EP-0141732-B1 | COSMETIC CLEANSING COMPOSITION, PARTICULARLY EYE MAKE-UP REMOVER | L'OREAL (FR) | 1988-05-11 | — | — | EP | claimed |
| EP-0141732-A2 | Cosmetic cleansing composition, particularly eye make-up remover | L'OREAL (FR) | 1985-05-15 | — | — | EP | claimed |
| US-20240108730-A1 | CORTICOSTEROID COMPOSITIONS | VIROPHARMA BIOLOGICS LLC (US) | 2024-04-04 | — | — | US | disclosed |
| US-11931227-B2 | Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding | COOK MEDICAL TECHNOLOGIES LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230255984-A1 | CORTICOSTEROID COMPOSITIONS | VIROPHARMA BIOLOGICS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11357859-B2 | Compositions for the treatment of gastrointestinal inflammation | VIROPHARMA BIOLOGICS LLC (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3970726-A1 | METHODS OF TREATMENT FOR ESOPHAGEAL INFLAMMATION | ViroPharma Biologics LLC (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3574914-B1 | CORTICOSTEROID COMPOSITIONS | VIROPHARMA BIOLOGICS LLC (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-2585075-B1 | METHODS OF TREATMENT FOR ESOPHAGEAL INFLAMMATION | MERITAGE PHARMA INC (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-2968651-B1 | ADHESIVE MEDICAL PRODUCTS AND METHODS FOR TREATING GASTROINTESTINAL LESIONS | COOK MEDICAL TECHNOLOGIES LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-5135480-A | Transdermal drug delivery device | ELAN TRANSDERMAL LIMITED (IE) | 1992-08-04 | — | — | US | disclosed |
| EP-0484186-A1 | Formulations and their use in the treatment of neurological diseases | ELAN CORPORATION, Plc (IE) | 1992-05-06 | — | — | EP | disclosed |
| US-4946853-A | Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method | ELAN TRANSDERMAL LIMITED (IE) | 1990-08-07 | — | — | US | disclosed |
| EP-0325843-A2 | Pharmaceutical formulations for preventing drug tolerance | ELAN CORPORATION PLC (IE) | 1989-08-02 | — | — | EP | disclosed |
| EP-0289342-A2 | Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method | ELAN TRANSDERMAL LIMITED (IE) | 1988-11-02 | — | — | EP | disclosed |
| EP-0141732-B1 | COSMETIC CLEANSING COMPOSITION, PARTICULARLY EYE MAKE-UP REMOVER | L'OREAL (FR) | 1988-05-11 | — | — | EP | disclosed |
| EP-0252732-A2 | Transdermal drug delivery device | ELAN TRANSDERMAL LIMITED (IE) | 1988-01-13 | — | — | EP | disclosed |
| EP-0141732-A2 | Cosmetic cleansing composition, particularly eye make-up remover | L'OREAL (FR) | 1985-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108730-A1 | CORTICOSTEROID COMPOSITIONS | NR3C1, SERPINA6, NR3C2 | POLB 4624/4885CA12 1632/4885CA1 2306/4885 |
| US-20230255984-A1 | CORTICOSTEROID COMPOSITIONS | NR3C1, SERPINA6, NR3C2 | POLB 4624/4885CA12 1632/4885CA1 2306/4885 |
| US-11357859-B2 | Compositions for the treatment of gastrointestinal inflammation | FABP2, FABP6, TNF | POLB 4580/4885CA12 1053/4885CA1 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.